HER2 is a protein involved in cell growth. Testing a tumor sample for HER2 can help identify treatments that may work against that cancer. In breast cancer reports, the result may include a protein-staining score and a gene test.
Immunohistochemistry (IHC) uses staining to show HER2 protein in tissue. Fluorescence in situ hybridization (FISH) examines copies of the HER2 gene in the cancer cells. They answer related but different questions.
An IHC score of 2+ is not enough on its own to call a tumor HER2-positive. A gene test helps complete the classification. An IHC score of 3+ usually indicates HER2-positive breast cancer.
Yes. Some breast cancers with low or very low amounts of HER2 may qualify for particular treatments. Eligibility depends on the full findings and treatment history. A negative or low result does not mean there is no cancer.
HER2 testing is also used in some other cancers. Their interpretation can differ, so the cancer type and the final laboratory conclusion matter.

BaluMed makes medicine understandable! Our extensive medical report explanation 'translates' complex medical terms from MRI findings and discharge summaries into easily understandable language. With a combination of artificial intelligence and medical expertise, we offer quickly available and reliable information.